Back to results
US 2006/0135458 A1Published application
Antiviral oligonucleotides
OwnerAndrew Vaillant, Jean-Marc Juteauinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerAndrew Vaillant, Jean-Marc Juteauinventors
Estimating the term…
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length and include chemical modifications, such as modified internucleotidic linkages and modifications at the 2′-position of the ribose moieties. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least one oligonucleotide that act by a sequence complementary mode of action.
An oligonucleotide, having at least 50% of its nucleotides in said oligonucleotide modified at the 2′-position of the ribose moiety and having at least 50% of its internucleotidic linkages modified, wherein said oligonucleotide has an antiviral activity against a target virus, said activity operating predominantly by a sequence independent mode of action.
An oligonucleotide as set forth in any one of REP 1001, REP 2001, REP 3007, REP 2004, REP 2005, REP 2006, REP 2007, REP 2008, REP 2017, REP 2018, REP 2020, REP 2021, REP 2024, REP 2036, A20, G20, C20, REP 2029, REP 2031, REP 2030, REP 2033, REP 2055, REP 2056, REP 2057, REP 2060 and REP 2107.
An antiviral pharmaceutical composition comprising a therapeutically effective amount of at least one pharmacologically acceptable, polypyrimidine oligonucleotide and a pharmaceutically acceptable carrier, wherein the antiviral activity of said oligonucleotide occurs principally by a sequence independent mode of action.
An oligonucleotide, having at least 50% of its internucleotidic linkages modified, wherein said oligonucleotide has an antiviral activity against a target virus, said activity operating predominantly by a sequence independent mode of action, said oligonucleotide comprising at least 80% of pyrimidine residues.
An antiviral pharmaceutical composition comprising a therapeutically effective amount of at least one pharmacologically acceptable, polypyrimidine oligonucleotide and a pharmaceutically acceptable carrier, wherein the antiviral activity of said oligonucleotide occurs principally by a sequence independent mode of action;
Dependencies are inferred from the claim text.